Jagsonpal Pharmaceuticals Limited — Investor Meet, 07-11-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Jagsonpal Pharma's Q2 FY26 revenue was INR 74.5 Cr, largely flat YoY due to temporary GST transition impact. H1 FY26 revenue grew 10% YoY to INR 150 Cr. Q2 PAT rose 10% to INR 12.6 Cr (17% margin), while H1 PAT surged 39% to INR 23.4 Cr (16% margin). The company maintains INR 160 Cr cash after paying INR 16.7 Cr dividend. New COO & CFO appointments strengthen leadership. Management expects stronger H2 performance, focusing on market penetration, women's health innovation, and inorganic growth, targeting 10% overall growth with an ROCE aspiration of 20%+.